REDCURE Registry for Chronic Kidney Disease (CKD) Anemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Daprodustat.
- Who it may be relevant to
- Registry conditions: CKD Anemia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Registry of Daprodustat in Chronic Kidney Disease (CKD) Anemia for Understanding Real-World Evidence (REDCURE)
Overview
A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat
Interventions
- Drug Daprodustat
Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug
Primary outcome measures
- Serum hemoglobin levels [Time frame: 3 months]
Secondary outcome measures (1)
- Frequency of MACE ( Major Adverse Cardiovascular Events) [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)
- Patients on hemodialysis (HD) or peritoneal dialysis (PD)
- Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent
Exclusion criteria
- Acute Kidney Injury (AKI) without underlying chronicity
- Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
- Refusal or inability to provide consent
- Current enrollment in an interventional trial that restricts real-world data collection
- Life expectancy < 3 months, where follow-up is not feasible
- Known contraindications to Daprodustat as per local prescribing information
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07346547 · NQ/DP/JES/Reg-006